Opinion

Video

Future of Myelofibrosis: Anticipated Data and Emerging Therapies

Aaron Gerds, MD, MS, explores the future landscape of myelofibrosis with insights from the 2003 ASH Annual Meeting and Exposition (ASH 2023), and delves into anticipated data on combination therapies and ongoing trials shaping the next phase of myelofibrosis treatment.

This is a video synopsis/summary of a Guidelines involving Aaron Gerds, MD, MS.

Gerds anticipates significant data from ASH 2023 ,focusing on the transformative potential of combination therapies in myelofibrosis. The spotlight is on the TRANSFORM-1 (NCT04472598) and the MANIFEST-2 (NCT04603495) clinical trials, both exploring combination therapies. Despite achieving primary end points of spleen volume reduction, secondary end points related to symptom burden were not met, prompting nuanced interpretations. Gerds stresses the importance of long-term follow-up to assess the durability of combination therapies. Beyond ASH 2023, he highlights promising emerging treatments, including the MDM-2 inhibitor navtemadlin and the IMPACT study (NCT02164513) with imetelstat, aiming to prolong survival. Acknowledging the dynamic landscape of myelofibrosis treatment, Gerds advises practitioners to collaborate with specialized centers for optimal patient care and participation in clinical trials, which is crucial for advancing the field. This segment provides insights into the evolving therapeutic landscape for myelofibrosis and underscores the need for ongoing research and collaboration.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

Related Videos
1 KOL is featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
1 KOL is featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo